INS and metabolic dysfunction-associated steatotic liver disease: No statistically significant associations with weight loss were found for sex, baseline blood pressure, NAFLD and ASCVD status, smoking status, the maximum dose of SGLT2i use, the use of other medications (e.g., metformin, pioglitazone, DPP-4 inhibitors, insulin, and calcium channel blockers), baseline HbA1c, changes in HbA1c, eGFR, or patients with an increase in creatinine of >30% after SGLT2i (Table 2).